Abstract: The gist of the invention consists in the therapeutic vaccine for treatment of diabetes type 1 in children, which contains Treg cells CD3(+)CD4(+)CD25(high)CD127(?). Claimed too is the cell sorter used to produce the vaccine and the method of multiplying Treg cells in vitro.
Type:
Grant
Filed:
December 22, 2017
Date of Patent:
April 2, 2024
Assignee:
Gdanski Uniwersytet Medyczny
Inventors:
Piotr Trzonkowski, Malgorzata Mysliwiec, Natalia Marek-Trzonkowska
Abstract: The subject of this invention is point mutants of human proteins constituting the complement system's C3 and C5 convertases, where the mutation are as follows: For the factor B: —D279G, F286L, K323E, Y363A; D279G_F286L_K323E_Y363A—quadruple mutant; For the C2 protein: —C261A, Q.263G, Y347A, L348A; T442Q, double mutants C261A_Q263G and Y347A_Q263G, triple mutant Y347A_Q263G_T442Q The subject of this invention is the method of enhancing the activity of the anti-cancer antibodies, which includes the addition of mutants defined above. The subject of this invention is the pharmaceutical composition, which includes the therapeutically effective number of mutants defined above. The subject of this invention is the use of mutants defined above to enhance the cytotoxic activity of anti-cancer antibodies in therapy and in the treatment of neoplastic diseases.
Type:
Grant
Filed:
April 3, 2019
Date of Patent:
August 16, 2022
Assignee:
GDANSKI UNIWERSYTET MEDYCZNY
Inventors:
Marcin Okroj, Anna Felberg-Mietka, Aleksandra Urban
Abstract: The invention relates to a new method for in vitro expansion of CD4+CD25HighCD127?/LOWfoxP3+Tregs, wherein the process of Treg expansion takes place permanently or temporarily at a temperature below 37° C., optimally at a temperature of 33° C., the isolated Tregs are expanded in SCGM or X-vivo-20 medium supplemented with human serum or with foetal bovine serum, and magnetic beads coated with anti-CD3 and anti-CD28 antibodies at 1:1 (cell:bead) ratio and interleukin-2 are added to the culture.
Type:
Grant
Filed:
December 19, 2016
Date of Patent:
July 27, 2021
Assignee:
GDANSKI UNIWERSYTET MEDYCZNY
Inventors:
Natalia Marek-Trzonkowska, Piotr Trzonkowski, Malgorzata Mysliwiec
Abstract: The gist of the invention consists in the therapeutic vaccine for treatment of diabetes type 1 in children, which contains Treg cells CD3(+)CD4(+)CD25(high)CD127(?). Claimed too is the cell sorter used to produce the vaccine and the method of multiplying Treg cells in vitro.
Type:
Application
Filed:
June 4, 2013
Publication date:
June 18, 2015
Applicant:
Gdanski Uniwersytet Medyczny
Inventors:
Piotr Trzonkowski, Malgorzata Mysliwiec, Natalia Marek-Trzonkowski
Abstract: A method of determination of the risk of distant metastases in surgically treated patients with non-small cell lung cancer in stage I-IIIA based on that a sample of primary tumor tissue is acquired, from which at least one microRNA is extracted which retrotranscripted into complementary DNA (cDNA) by reverse transcription, wherefore microRNA in examined sample is quantificated with the use of quantitative PCR method while the expression value of each microRNA is referred to the reference expression values in a recurrence prediction model in which the expression values are correlated to the high and low risk of distant metastases is characterized by that the expression value of only one from twenty two microRNAs listed below in Table 1 in primary tumor tissue of non-small cell lung cancer is measured.